Agilex has offered our clients small molecule solutions that lead to their success. Agilex Biolab...
15
Jun
Applying Decades of Experience with an Eye on the Future of Small Molecule Development For decade...
We took some time to sit down and talk with Cameron so you could get to know him a bit better......
A Quick Look at Agilex Biolabs' Expertise and Capabilities In the intricate landscape of drug dis...
Agilex Biolabs has extensive knowledge on small molecule development and pharmacokinetic services....
Small and large molecule drug development often necessitates distinct analytical methodologies. Agil...
Agilex has extensive experience developing and validating like-binding assays for specific immune-on...
How do Australia's streamlined regulatory process and global tax incentive apply to your toxicology...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent....
Faster reporting, integrated expertise, and growing scientific capability. One year after launching its in-house pharmacokinetic data analysis service, Agilex Biolabs reflects on how an integrated bioanalysis and PK model is helping sponsors accelerate clinical development decisions.
Immunogenicity testing is due for a rethink, as modern drug development shifts from rigid frameworks to smarter, clinically driven strategies.
Oligonucleotide therapeutics are transforming modern medicine, but analysing them is anything but simple. This article breaks down the three core challenges of oligonucleotide bioanalysis and the regulatory-ready LC-MS strategies required to generate reliable, submission-quality data.
Agilex Biolabs expands with a new Flow Cytometry Laboratory at QIMR Berghofer, boosting speed and precision in clinical research.
Contracted by the South Australian Government, Agilex Biolabs is deploying world-class science to sa...
Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new....
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No...
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the ris...
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in c...
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agi...
